Accurate measurement of blood glucose concentration is essential for achieving safe and efficacious glucose control in the intensive care unit (ICU) 2 (1, 2 ). Accuracy standards to determine adequacy of intermittent and continuous glucose monitoring devices are subject to ongoing debate informed by consensus but lacking convincing evidence (3 ) .
Various types of glucose measuring devices are currently used in the ICU. A limited number of studies report the use of subcutaneous continuous glucose monitors (CGMs) (4 -9 ) , and the majority of glucose measurements are currently performed intermittently by use of either blood gas analyzers or point-of-care (POC) glucose meters. Although blood gas analyzers have been shown to be accurate (10 ) , the use of POC meters has raised many concerns (11) (12) (13) . The POC devices that measure glucose concentration in either arterial or capillary blood were not designed for use in critically ill patients who are prone to frequent and often large changes in hematocrit, pH, and blood oxygenation. Intermittent measurements are also limited by the heavy workload at the ICU and could lead to missing important events such as hypoglycemia episodes.
In response to these concerns, and also to increase the frequency of blood glucose measurements without affecting staff workload, CGM devices are being developed for use in the critically ill. Intravenous and subcutaneous CGM systems are now available for clinical use and have undergone early clinical testing (14 -17 ) . CGM technologies offer frequent automated glucose measurements, a glucose rate-of-change assessment, and threshold or predictive alarm functionality. These properties may positively impact the safety of current glucose control protocols and improve clinical outcomes (18 ) .
Potential benefits may be substantial but should be evaluated and documented to attain regulatory approvals, reimbursement, and clinical acceptance. To date, no studies have assessed glucose control measures obtained from use of continuous glucose monitoring compared with intermittent glucose measurements. Such direct comparison could provide valuable data to help inform the debate on accuracy guidelines. Two approaches to perform comparison studies are feasible. Clinical trials may be conducted, but these are costly, time-consuming, and bounded by ethical constraints. Computer simulations offer a resource efficient alternative (19, 20 ) . In the present study, we used a validated virtual population of 56 critically ill patients (21 ) to simulate clinical experiments and compare glucose control measures by use of 3 commonly used glucose control protocols informed by either intermittent or continuous glucose measurements.
Materials and Methods
We used computer simulations to contrast the ability of continuous and intermittent glucose measurements to achieve desirable glucose concentrations in combination with common glucose protocols in the critically ill. This allowed direct comparison, similar to that offered by crossover clinical trials, among glucose measurement methods (continuous vs intermittent) and glycemic control protocols. The simulated experiments used a virtual population of critically ill patients, developed from data collected in multicenter multinational clinical trials (22) (23) (24) (25) (26) and validated against independent clinical data (21 ) .
VIRTUAL PATIENTS
The virtual patients were created from clinical database collected in 56 critically ill patients, 29 patients treated in the medical ICU [25 men age 66.7 (11.7) years; weight 76.5 (14.6) kg, 5 with diabetes; acute physiology and chronic health evaluation II (APACHE II) score 19 (16 -24) ; total carbohydrate intake 7.2 (3.8) g/h] and 27 in the surgical ICU [16 men age 62.6 (13.7) years; weight 83.5 (18.4) kg, 7 with diabetes; APACHE II 22 (19 -25) ; total carbohydrate intake 7.5 (3.5) g/h] at Charles University, Prague, Czech Republic (22, 23 ) ; Medical University, Graz, Austria (23, 24 ) ; Katholieke Universiteit, Leuven, Belgium (25, 26 ) ; and Royal Brompton Hospital, London (23, 25 ) .
From the clinical data, 56 virtual patients were created, 1 virtual patient per 1 real patient, through a process termed experimental in silico cloning (19 ) . A physiologically based compartment model was fitted to glucose measurements capturing the between-person and temporal variability in insulin sensitivity as well as institutional differences in nutritional and other treatment protocols (19 ) .
We assessed the validity of the virtual population replicating 2 open-label randomized clinical trials evaluating glucose control protocols (25, 27 ) . One study compared performance of the enhanced model predictive control algorithm at 2 ICUs in the UK and Belgium (25 ) . The other study compared 3 algorithms for insulin delivery in a single ICU in Prague (27 ) . Principal findings of the 2 studies were reproduced (21 ) .
SIMULATIONS DESIGN
We simulated a 48-h stay in the ICU. When evaluating intermittent glucose measurements, insulin delivery was adjusted according to the glucose measurement pertinent at the protocol-defined time points, i.e., hourly or less frequently. When evaluating continuous glucose measurements, available every 5 min, insulin delivery was adjusted at the protocol-defined time points as for the intermittent measurements, and additionally at hypoglycemia and hyperglycemia alarm thresholds set at 70 mg/dL (3.9 mmol/L) and 300 mg/dL (16.7 mmol/L). Once activated, alarms were disabled over the following 30 min. Protocol-specific hypoglycemia and hyperglycemia treatment guidelines were applied.
Further simulated experiments assessed sensitivity and specificity of CGM-triggered hypoglycemia alarms. An alarm was considered true positive if it occurred within 30 min from the start of blood glucose (BG)-confirmed hypoglycemia event. If hypoglycemia did not occur within 30 min of the start of the alarm, the alarm was considered false positive. In these simulations, hypoglycemia treatment was not administered, as it confounded the assessment of alarm sensitivity and specificity.
GLUCOSE PROTOCOLS
We simulated 3 common glucose protocols: Yale (28 ) (target range 100 -140 mg/dL or 5.6 -7.8 mmol/L; hypoglycemia thresholds 75 and 60 mg/dL or 4. 
CGM MEASUREMENT ERROR
The CGM measurement error combined scale, bias, and residual error components. The scale was expressed as a proportional error pivoted around blood glucose of 100 mg/dL (5.55 mmol/L). The constant bias was applied across the entire glucose range. The residual error was assumed to be autocorrelated with zero mean, normally distributed, and absolute at blood glucose values Ͻ100 mg/dL (5.55 mmol/L) and proportional otherwise.
Seven levels of the scale component (range 0.8 -1.2 in steps of 0.1) were considered. The constant bias ranged from Ϫ15 mg/dL (Ϫ0.84mmol/L) to 15 mg/dL (0.84 mmol/L) in 7 steps of 5 mg/dL (0.28 mmol/L). The residual error was assumed to have an SD ranging from 0 to 15 mg/dL (0.84 mmol/L) for blood glucose Ͻ100 mg/dL (5.55 mmol/L), and a CV from 0% to 15% for other glucose values. Seven steps with resolution of 2.5 mg/dL (0.14 mmol/L) of SD and 2.5% of CV were considered. We applied 3 levels of the autocorrelation coefficient, 0.97, 0.98, and 0.99, to glucose values sampled every minute. Overall, 735 combinations of the 3 error components were simulated. We stratified the total error obtained in the simulations according to the mean absolute relative deviation (MARD) into ranges 0%-5%, 5%-10%, and 10%-15%. Sixty error combinations per virtual subject were randomly selected, 20 for each MARD range, and used in subsequent simulated experiments. Different error combinations could be selected for different subjects.
We carried out additional analyses to assess the effect of CGM imprecision and bias on glucose control and rate and duration of hypoglycemia. CGM imprecision was varied between 0% and 15% in 5% steps in the absence of bias. Similarly, CGM bias varied from Ϫ15% to 15% in 5% steps in the absence of imprecision.
INTERMITTENT GLUCOSE MEASUREMENT ERROR
Three intermittent glucose measurement methods were simulated: arterial blood gas (ABG) measurement, a POC device with capillary blood, and a POC device with arterial blood (POC arterial). The measurement error was assumed to be uncorrelated and normally distributed with zero mean and with characteristics reported by a systematic review by Inoue et al. (10 ) . ABG, POC arterial and POC capillary measurement errors were assumed absolute Ͻ75 mg/dL (4.2 mmol/L) with a constant SD of 2.3 mg/dL (0.13 mmol/ L), 5.8 mg/dL (0.32 mmol/L), and 8.0 mg/dL (0.44 mmol/L), respectively. For glucose values Ͼ75 mg/dL (4.2 mmol/L), the measurement error was assumed to be proportional, with a CV at 3.2%, 6.0%, and 7.8% for ABG, POC arterial, and POC capillary measurements. 
STATISTICS
Glycemia control measures were based on error-free blood glucose concentration. Hypoglycemia measures included the percentage of simulated patients experiencing Ն1 episode of hypoglycemia (Ͻ70 and Ͻ40 mg/dL or Ͻ3.9 and Ͻ2.2 mmol/L) and the median duration of such episodes across simulated studies. Values shown are mean (SD) or median (interquartile range).
Results
In total, 20 160 48-h-long simulated experiments were generated, a result of multiplication of 20 error combinations, 56 virtual subjects, 6 measurement methods (3 ranges of CGM error plus 3 intermittent methods), and 3 ICU protocols. Three-quarters of the simulated experiments (15 120) were used in the data analysis, providing 560 simulated experiments per ICU protocol and per measurement method. Further selection was carried out to obtain an equal representation of virtual ICU subjects in each MARD range and to ensure an equal number of simulated experiments in each MARD range. The selection process adopted random sampling from allowable subsets (see details in Supplemental Information, which accompanies the online version of this article at http://www.clinchem.org/content/vol60/ issue12). Table 1 shows glucose control measures stratified according to the glucose measurement method and the glucose control protocol. Apart from the Washington protocol, CGM with MARD Յ15% resulted in similar mean glucose as with the use of intermittent BG mea- surements. Adopting the University of Washington protocol, the mean glucose was higher when CGM was used, but this was offset by lower rates of hypoglycemia. Glucose variability was similar across all measurement methods and protocols. The time spent in target glucose range improved with increased CGM accuracy applying the Yale and Washington protocols, reaching similar values as with the use of intermittent BG measurement methods when CGM MARD was Ͻ10%. Applying the NICE-SUGAR protocol, the time spent in target glucose range was largely unaffected by the glucose measurement method. Hypoglycemia measures are shown in Table 2 . The frequency and duration of hypoglycemia episodes was reduced or similar for CGM measurements with MARD Յ10% across all protocols. For CGM measurements with MARD in the upper 10%-15% range, the frequency and duration of hypoglycemia Ͻ40 mg/dL (Ͻ2.2 mmol/L) was also reduced, but hypoglycemia Ͻ70 mg/dL (3.9 mmol/L) was reduced only while applying the Washington and NICE-SUGAR protocols.
Online Supplemental Table 1 shows the sensitivity and specificity of CGM-based hypoglycemia alarms. Sensitivity was reduced with CGM measurements with MARD Ͼ10%. Specificity was also reduced Ͼ10% MARD apart from the Yale protocol, where it remained similar across the investigated MARD range. Table 3 shows glycemic control measures stratified according to CGM imprecision. Apart from the Yale protocol, CGM with imprecision Յ15% resulted in a similar mean glucose and glucose SD. With the Yale protocol, CGM imprecision of 15% resulted in a higher mean glucose and higher glucose variability, leading to a reduction of time spent in target glucose range. The effect of CGM imprecision on frequency and duration of hypoglycemia is shown in Table 4 . An increase in the number of hypoglycemia episodes, but not the duration, was seen with increasing imprecision in all 3 protocols. Table 5 shows the effect of CGM bias on glucose control. As expected, a reduction in mean glucose with increasing bias was observed in all protocols. A marked reduction in time spent in target glucose range was present in all protocols, with negative bias Յ10%. With the Yale protocol, both positive and negative bias Ͼ10% resulted in reduced time spent in the target glucose range. With the Washington protocol, time spent in target range was least affected by positive bias, whereas with the NICE-SUGAR protocol, the time spent in target range increased with increasing positive bias.
The effect of CGM bias on frequency and duration of hypoglycemia is shown in Table 6 . An increase in the number of hypoglycemia episodes Ͻ70 mg/dL (3.9 mmol/L) with increasing bias was evident with all protocols, although at a different bias threshold. The Yale protocol was sensitive to positive CGM bias, with the number of hypoglycemic episodes steadily increasing with increasing positive bias. The NICE-SUGAR protocol was the least sensitive. A marked increase in the number of hypoglycemia episodes Ͻ70 and 40 mg/dL (3.9 and 2.2 mmol/L) was observed at bias Ն10%.
Discussion
The present study assessed the level of accuracy of continuous glucose monitoring required for safe and efficacious glycemic control in the ICU by contrasting glucose control measures obtained with 3 common insulin titrating protocols. Experiments using intermittent and continuous glucose measurements demonstrated comparable efficacy of CGM-informed and BG-informed ICU insulin protocols in terms of mean glucose and glucose variability across all levels of CGM error and protocols. The time spent in the target glucose range was similar for CGM error Յ10% but decreased thereafter. Hypoglycemia rates were maintained or improved with CGM error Յ10% MARD. The frequency and duration of severe hypoglycemia Ͻ40 mg/dL (2.2 mmol/L) was reduced across the investigated MARD range. Unlike the Yale and NICE-SUGAR protocols, which provided similar mean glucose across all measurement methods, mean glucose associated with the CGM-driven Washington protocol was higher and was offset by a considerably reduced frequency of hypoglycemia (Table 2) . A reduction in hypoglycemia frequency was also observed in the CGM-driven Yale protocol, but only with MARD Ͻ10%. With MARD values Ͼ10%, both frequency and duration of hypoglycemia events were higher than using intermittent BG measurements. In contrast, the CGMinformed NICE-SUGAR protocol resulted in a similar frequency of hypoglycemia Ͻ70 mg/dL (3.9 mmol/L) as with intermittent BG measurements.
Glucose control measures were protocol dependent, so the type of protocol had a larger effect on end points than the glucose measurement method. This applied to mean glucose, glucose variability, and hypoglycemia rates and duration. The efficacy of the CGM-driven Washington protocol measured as a percentage of time glucose was in target range was offset by the high frequency of hypoglycemia episodes compared with the other 2 ICU protocols. In contrast, the NICE-SUGAR protocol had fewer hypoglycemia episodes but also the lowest percentage of time spent with glucose in the target range. Of the 3 ICU protocols, the Yale protocol appeared to be the safest, with the lowest rates of hypoglycemia while attaining mean glucose similar to that of the Washington protocol.
CGM-triggered alarms are designed to facilitate timely detection of hypo-and hyperglycemia and may improve the safety of existing protocols. We documented acceptable sensitivity and specificity of hypoglycemia alarms at MARD Յ10% and then gradual deterioration in sensitivity and specificity. This finding was consistent across all protocols.
The insulin-titrating protocols achieved different balances between safety, as measured by hypoglycemia exposure, and efficacy, as assessed by time spent in the target range. The NICE-SUGAR protocol emphasized hypoglycemia avoidance at the expense of higher glucose concentrations, whereas with the Washington protocol the emphases were reversed. The Yale protocol was most balanced, with 50% of time spent in a tight glucose range and a low risk of hypoglycemia.
Additional analyses contrasted CGM imprecision and bias. In agreement with Boyd and Bruns (20 ) , we observed a smaller effect of imprecision on mean glucose and time spent in the target range compared to bias. This observation extended to frequency and duration of hypoglycemia in the case of the Yale and NICE-SUGAR protocols but not with the Washington protocol. In the latter protocol, the effect of increasing CGM imprecision on the number of hypoglycemia events was more pronounced than the effect of bias. The results from this additional analysis support our main finding that glucose control measures are protocol dependent.
The partial difference between our observations and those by Boyd and Bruns (20 ) on the effect of imprecision can be explained by the different ways CGM concentrations informed glucose protocols. In the present study, a single CGM value pertinent to the protocol-directed control time was used. Boyd and Bruns used linear regression analysis to interpolate CGM measurements between 2 control times, and in case of hourly sampling, 12 CGM measurements (1 every 5 min) were used to derive the glucose concentration at the control time, informing the protocol and mitigating the effect of imprecision. The authors of this recent study (20 ) indicated that when CGM was used to raise alarms between algorithm-defined time points, the commonly used glucose control metrics remained unchanged. The results of our study confirm this finding for some of the studied protocols but not for others, adding an emphasis on protocol dependence.
Originally, the 3 protocols were designed for the use with intermittent glucose measurements. Apart from the benefit of anytime display of glucose concentration, additional information provided by continuous glucose measurement devices such as glucose trending, hypo/hyperglycemia alarms, and predictive alarms could lead to further refinements of existing protocols or may stimulate the development of novel protocols with enhanced performance, but this is outside the scope of the present work.
Simulations have limitations but offer the only practical approach given the prohibitive cost and ethical dilemmas associated with conducting similar evaluations as large-scale clinical trials. It is important that virtual populations represented by a simulation model of glucose regulation are validated and predictions confirmed. In our previous work, we carefully considered these aspects and, apart from developing our virtual population from clinical data and applying it on a 1-to-1 basis (1 virtual subject per 1 critically ill patient), we validated predictions by replicating glucose control measures of comparative clinical studies (21 ) . Others used simulations to evaluate the effect of measurement error on glucose control in the ICU (13, 30 -31 ) using intermittent BG measurements. Our study expands these findings by contrasting intermittent and continuous glucose measurements and simulating an intended use of CGM with currently available ICU protocols, i.e., advising on insulin delivery at protocol time points and, additionally, at times of CGM-triggered alarms. Validation of our observations in an appropriately designed clinical study is desirable but is logistically and ethically challenging.
Accuracy of glucose meters in the ICU has been studied extensively (10 -13 ) although accuracy guidelines and standards are being debated. Existing stan- In conclusion, the efficacy of CGM-informed and BG-informed common glucose protocols is similar with MARD Յ15%, but the risk of hypoglycemia may be reduced by use of CGM with MARD Յ10%. Protocol choice has greater influence on glucose control measures than the glucose measurement method. Continuous glucose monitoring may stimulate the development of novel, more efficacious, and safer glucose control protocols than those currently available.
